Saxagliptin

Type: Keyphrase

Name: Saxagliptin

First reported May 21 2013 - Updated May 21 2013 - 2 reports

Onglyza Becomes Seventh DPP-4 Inhibitor In Japan

The manufacture Onglyza (saxagliptin), a DPP-4 inhibitor, was approved in Japan March 25. ... [Published The Rose Sheet - May 21 2013]

Entities: DPP-4, Onglyza, Japan

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Added benefit of saxagliptin/metformin combination is not proven

http://www.for-diabetes.com/added-benefit-of-saxagliptinmetformin-combination-is-not-proven The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of iabetes mellitus. ... [Published Now Public - May 15 2013]

Entities: Saxagliptin, Metformin, IQWiG, Komboglyze, AMNOG

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Added benefit of saxagliptin/metformin combination is not proven

The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the "Act on the Reform of the Market ... [Published EurekAlert! - Apr 29 2013]

Entities: Saxagliptin, Metformin, Insulin

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

AstraZeneca PLC

Earnings battered but AZ optimistic for future growth

AstraZeneca has posted a 13% decline in first-quarter revenues to $6.39 billion, due to the loss of exclusivity on key brands, but analysts believe things are starting to improve at the Anglo-Swedish drugmaker.Core operating profit was down 25% to $2.32 ... [Published Pharma Times - Apr 25 2013]

Entities: Brilinta, AstraZeneca PLC, Pascal Soriot, Crestor

First reported Apr 20 2013 - Updated Apr 20 2013 - 1 reports

SITAGLIPTIN

More » Report Shows Byetta, Januvia and Other Incretin Mimetic Drugs for Type 2 Diabetes

According to the Institute for Safe Medication Practices? most recent QuarterWatch report, incretin mimetic drugs such as Byetta, Januvia and Victoza may be 25 times more likely to be linked to pancreatic cancer. This class of medications is currently ... [Published Yahoo! News - Apr 20 2013]

Entities: Byetta, SITAGLIPTIN, Victoza, Pancreatic Cancer, pancreatitis

First reported Apr 17 2013 - Updated Apr 17 2013 - 1 reports

Correction to Kinetic and Mechanistic Insight into the Thermodynamic Degradation of Saxagliptin

Log in with your ACS ID. If you do not have an ACS ID, please register for one.ACS IDs are free, and you do not need to be a member to register.ACS ID: Password ... [Published Journal of Organic Chemistry - Apr 17 2013]

Entities: Saxagliptin, Degradation

First reported Jan 18 2013 - Updated Jan 18 2013 - 2 reports

Pending EC decision: Komboglyze, saxagliptin / metformin hydrochloride, Opinion date: 17-Jan-2013

[Published Pending EC decisions and European Public Assess ... - Jan 18 2013]

Entities: Saxagliptin, Metformin Hydrochloride, Komboglyze

Quotes

...M Benjamin, MD, FACP, Director of Healthcare Quality at Baystate Medical Center and assistant professor at Tufts University School of Medicine, "Judicious use of SMBG data can help to improve glycemic control, select an anti-diabetic regimen, and provide powerful feedback to patients wishing to improve metabolic control." In 2008, the ADA concluded and published in its Standard of Medical Care, that blood glucose monitoring helps in the planning of meals, activities, and...

LabStyle Innovations - Glucose Monitoring For The Mobile Age [Published Seeking Alpha - May 15 2013]

...In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German (IQWiG) examined whether this fixed combination product offers an added benefit versus the current standard treatment...

Added benefit of saxagliptin/metformin combination is not proven [Published EurekAlert! - Apr 29 2013]

...He added that "Brilinta, the diabetes franchise, emerging markets, Japan and our respiratory products have all made good progress and we continued to invest in distinctive science that will advance our knowledge of disease physiology and help to identify new drug targets"

Earnings battered but AZ optimistic for future growth [Published Pharma Times - Apr 25 2013]

And our last report about Victoza was in November 2012: "The Drug-Induced Pancreatitis Safety Problem That Hangs Around Victoza Gets Another Look"

Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta, Januvia, An ... [Published Drug Injury Watch - Mar 18 2013]

More Content

sort by: Date \| Relevance
Potential Lawsuit: Diabetes Medication Lawsuits [Published Lawyers & Settlements - May 21 2013]
Onglyza Becomes Seventh DPP-4 Inhibitor In Japan [Published The Rose Sheet - May 21 2013]
Onglyza Becomes Seventh DPP-4 Inhibitor In Japan [Published BioPortfolio - May 21 2013]
LabStyle Innovations - Glucose Monitoring For T... [Published Seeking Alpha - May 15 2013]
Added benefit of saxagliptin/metformin combinat... [Published Now Public - May 15 2013]
Alleged Januvia Pancreatic Cancer Lawsuits Offe... [Published PRWeb - May 10 2013]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - May 03 2013]
Added benefit of saxagliptin/metformin combinat... [Published EurekAlert! - Apr 29 2013]
Earnings battered but AZ optimistic for future ... [Published Pharma Times - Apr 25 2013]
More » Report Shows Byetta, Januvia and Other I... [Published Yahoo! News - Apr 20 2013]
Correction to Kinetic and Mechanistic Insight i... [Published Journal of Organic Chemistry - Apr 17 2013]
Emerging Drug Safety Issue: Possible Increased ... [Published Drug Injury Watch - Mar 18 2013]
FDA Investigating Januvia, Byetta and Other Dia... [Published PRWeb - Mar 15 2013]
Deals Of The Week Untangles The String of Pearls [Published The IN VIVO Blog - Mar 08 2013]
Pending EC decision: Komboglyze, saxagliptin / ... [Published Pending EC decisions and European Public Assess ... - Jan 18 2013]
Pending EC decision: Onglyza, saxagliptin, Opin... [Published Pending EC decisions and European Public Assess ... - Jan 18 2013]
M&A Deal of the Year Nominee Bristol-Myers/Amyl... [Published The IN VIVO Blog - Dec 18 2012]
AstraZeneca doubles workforce to launch product... [Published Topnews.in - Apr 05 2010]
AstraZeneca ramping Indian workforce [Published Topnews.in - Apr 03 2010]